OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Access to investigational drugs has been a controversial topic during the COVID19 pandemic: what is the level of evidence required? How do we evaluate individual access requests, particularly from public figures such as outgoing Presidents? How does providing access change the ability to acquire fundamental information about these products? In May 2018, the Right to Try Act was signed into law, creating a new pathway for patients with life-threatening conditions to access investigational products prior to FDA approval. Prior to the federal law, more than half of states had passed their own versions of right to try. Two expert panelists will consider the scientific, legal, and ethical issues relating to access to investigational treatments and how Right to Try laws change the landscape for the future
